NASDAQ:CBIO Crescent Biopharma (CBIO) Stock Price, News & Analysis $11.00 -0.60 (-5.17%) As of 08/6/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesSEC FilingsSustainabilityTrendsBuy This Stock About Crescent Biopharma Stock (NASDAQ:CBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Crescent Biopharma alerts:Sign Up Key Stats Today's Range$10.90▼$11.7750-Day Range N/A52-Week Range$10.90▼$63.00Volume34,921 shsAverage Volume137,191 shsMarket Capitalization$215.05 millionP/E RatioN/ADividend YieldN/APrice Target$25.67Consensus RatingStrong Buy Company Overview Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA. Read More Crescent Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCBIO MarketRank™: Crescent Biopharma scored higher than 60% of companies evaluated by MarketBeat, and ranked 770th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingCrescent Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCrescent Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Crescent Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Crescent Biopharma are expected to grow in the coming year, from ($0.16) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crescent Biopharma is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crescent Biopharma is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrescent Biopharma has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CBIO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrescent Biopharma does not currently pay a dividend.Dividend GrowthCrescent Biopharma does not have a long track record of dividend growth. Sustainability and ESG3.7 / 5Environmental Score-0.84 Short InterestThere is no current short interest data available for CBIO. News and Social Media2.0 / 5News Sentiment-0.46 News SentimentCrescent Biopharma has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Crescent Biopharma this week, compared to 0 articles on an average week.Search Interest4 people have searched for CBIO on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows1 people have added Crescent Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Crescent Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Crescent Biopharma is held by insiders.Percentage Held by Institutions75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crescent Biopharma's insider trading history. Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CBIO Stock News HeadlinesCrescent Biopharma (NASDAQ:CBIO) Rating Lowered to "Sell" at Wall Street ZenAugust 4 at 3:27 AM | americanbankingnews.comCrescent Biopharma: Q2 Earnings SnapshotJuly 31, 2025 | sfgate.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsJuly 31, 2025 | finance.yahoo.comCrescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsJuly 31, 2025 | globenewswire.comWedbush Initiates Coverage of Crescent Biopharma (CBIO) with Outperform RecommendationJuly 15, 2025 | msn.comCrescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific OfficerJuly 8, 2025 | globenewswire.comCrescent Biopharma, Inc. Common Stock (CBIO) Analyst ResearchJuly 2, 2025 | nasdaq.comSee More Headlines CBIO Stock Analysis - Frequently Asked Questions How have CBIO shares performed this year? Crescent Biopharma's stock was trading at $15.7950 at the start of the year. Since then, CBIO stock has decreased by 30.4% and is now trading at $11.00. How were Crescent Biopharma's earnings last quarter? Crescent Biopharma, Inc. (NASDAQ:CBIO) released its earnings results on Thursday, July, 31st. The biopharmaceutical company reported ($4.93) EPS for the quarter, missing analysts' consensus estimates of ($2.69) by $2.24. When did Crescent Biopharma's stock split? Crescent Biopharma's stock reverse split on the morning of Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Crescent Biopharma? Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crescent Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV). Company Calendar Last Earnings7/31/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO Previous SymbolNASDAQ:CBIO CIK1253689 Webwww.crescentbiopharma.com Phone617-465-0586Fax336-480-2107Employees50Year Founded2003Price Target and Rating Average Price Target for Crescent Biopharma$25.67 High Price Target$28.00 Low Price Target$22.00 Potential Upside/Downside+133.3%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($34.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-106.06% Return on Assets-86.60% Debt Debt-to-Equity RatioN/A Current Ratio9.21 Quick Ratio9.21 Sales & Book Value Annual Sales$10 thousand Price / Sales21,505.00 Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book1.59Miscellaneous Outstanding Shares19,550,000Free Float18,768,000Market Cap$215.05 million OptionableNo Data Beta1.51 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CBIO) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.